Cancers, Vol. 11, Pages 1091: Glioblastoma: State of the Art and Future Perspectives Cancers doi: 10.3390/cancers11081091 Authors: Tabatabai Wakimoto This special issue is dedicated to glioblastoma and elucidates this disease from differentperspectives [...]
Cancers, Vol. 11, Pages 1092: Combination of Whole-Brain Radiotherapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Improves Overall Survival in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases Cancers doi: 10.3390/cancers11081092 Authors: Chen Lee Chuang Hung Huang Chong Brain metastases (BM) cause morbidity and mortality in patients with non-small cell lung cancer (NSCLC). The use of upfront epidermal growth factor receptor...
Cancers, Vol. 11, Pages 1087: Novel Apoptosis-Inducing Agents for the Treatment of Cancer, a New Arsenal in the Toolbox Cancers doi: 10.3390/cancers11081087 Authors: Lim Greer Lipkowitz Takebe : Evasion from apoptosis is an important hallmark of cancer cells. Alterations of apoptosis pathways are especially critical as they confer resistance to conventional anti-cancer therapeutics, e.g., chemotherapy, radiotherapy, and targeted therapeutics. Thus, successful induction of...
Cancers, Vol. 11, Pages 1088: Targeted Killing of Monocytes/Macrophages and Myeloid Leukemia Cells with Pro-Apoptotic Peptides Cancers doi: 10.3390/cancers11081088 Authors: Sioud Pettersen Ailte Fløisand Several cells of myeloid origin, such as monocytes and macrophages are involved in various human disorders, including cancer and inflammatory diseases. Hence, they represent attractive therapeutic targets. Here we developed three lytic hybrid peptides, by fusing a monocyte-...
Cancers, Vol. 11, Pages 1085: Current State of Liver-Directed Therapies and Combinatory Approaches with Systemic Therapy in Hepatocellular Carcinoma (HCC) Cancers doi: 10.3390/cancers11081085 Authors: Pedro Viveiros Ahsun Riaz Robert J. Lewandowski Devalingam Mahalingam The increasing set of liver-directed therapies (LDT) have become an integral part of hepatocellular carcinoma (HCC) treatment. These range from percutaneous ablative techniques to arterial embolization, and varied...
Cancers, Vol. 11, Pages 1089: Immune Resistance and EGFR Antagonists in Colorectal Cancer Cancers doi: 10.3390/cancers11081089 Authors: Giordano Remo Porras Pancione : Targeting the epidermal growth factor receptor (EGFR) either alone or in combination with chemotherapy in patients with RAS wild type metastatic colorectal cancer (mCRC) has revolutionized the treatment of CRC, but with less results than initially envisaged. In recent years, the discovery of multiple pathways...
Cancers, Vol. 11, Pages 1086: New Insight into Therapies Targeting Angiogenesis in Hepatocellular Carcinoma Cancers doi: 10.3390/cancers11081086 Authors: Mossenta Busato Baboci Cintio Toffoli Bo Hepatocellular carcinoma (HCC) is a malignancy characterized by neoangiogenesis that is determined by an augmented production of proangiogenesis factors by tumor and adjacent cells. This unbalanced angiogenesis process is a key feature of HCC carcinogenesis and progression....
Cancers, Vol. 11, Pages 1090: Novel Semi-Replicative Retroviral Vector Mediated Double Suicide Gene Transfer Enhances Antitumor Effects in Patient-Derived Glioblastoma Models Cancers doi: 10.3390/cancers11081090 Authors: Lee Kim Lee Kang Shin Oh Koo Kim Kim Kong Nam Lee As glioblastomas are mostly localized infiltrative lesions, gene therapy based on the retroviral replicating vector (RRV) system is considered an attractive strategy. Combinations...
Cancers, Vol. 11, Pages 1084: Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child–Pugh A Liver Function: A Proof-Of-Concept Study Cancers doi: 10.3390/cancers11081084 Authors: Masatoshi Kudo Kazuomi Ueshima Stephan Chan Tomohiro Minami Hirokazu Chishina Tomoko Aoki Masahiro Takita Satoru Hagiwara Yasunori Minami Hiroshi Ida Mamoru Takenaka Toshiharu Sakurai Tomohiro Watanabe...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου